Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation

Regorafenib is one option for second‐line treatment of hepatocellular carcinoma (HCC), improving overall survival (OS) of sorafenib‐tolerant patients who develop progression. We aim to evaluate the safety and outcomes of regorafenib as second‐line treatment for HCC recurrence after liver transplanta...

Full description

Saved in:

Bibliographic Details
Published in:	American journal of transplantation Vol. 19; no. 11; pp. 3176 - 3184
Main Authors:	Iavarone, Massimo, Invernizzi, Federica, Czauderna, Carolin, Sanduzzi‐Zamparelli, Marco, Bhoori, Sherrie, Amaddeo, Giuliana, Manini, Matteo A., López, Miguel F., Anders, Margarita, Pinter, Matthias, Rodríguez, Maria J. B., Cristóbal, Mario R., Soteras, Gabriel A., Piñero, Federico, Villadsen, Gerda E., Weinmann, Arndt, Crespo, Gonzalo, Mazzaferro, Vincenzo, Regnault, Helene, Giorgio, Massimo De, González‐Diéguez, Maria L., Donato, Maria F., Varela, Maria, Wörns, Marcus‐Alexander, Bruix, Jordi, Lampertico, Pietro, Reig, Maria
Format:	Journal Article
Language:	English
Published:	United States Elsevier Limited 01-11-2019
Subjects:	Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use cancer/malignancy/neoplasia Carcinoma, Hepatocellular - pathology Carcinoma, Hepatocellular - surgery Chemotherapy clinical research/practice Decision making drug interaction Drug Resistance, Neoplasm - drug effects Female Follow-Up Studies Graft rejection Hepatocellular carcinoma Humans Immunosuppressive agents Inhibitor drugs Liver cancer Liver Neoplasms - pathology Liver Neoplasms - surgery Liver transplantation Liver Transplantation - adverse effects liver transplantation/hepatology Liver transplants Male Middle Aged Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - etiology Neoplasm Recurrence, Local - pathology Patients pharmacology Phenylurea Compounds - administration & dosage Plasma levels Prognosis Pyridines - administration & dosage Retrospective Studies Safety side effects Sorafenib - administration & dosage Targeted cancer therapy Young Adult clinical research/practice drug interaction pharmacology side effects cancer/malignancy/neoplasia chemotherapy liver transplantation/hepatology
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Regorafenib is one option for second‐line treatment of hepatocellular carcinoma (HCC), improving overall survival (OS) of sorafenib‐tolerant patients who develop progression. We aim to evaluate the safety and outcomes of regorafenib as second‐line treatment for HCC recurrence after liver transplantation (LT). This is a retrospective, multicenter, international study including regorafenib‐treated LT patients (2015‐2018), with analysis of baseline characteristics and evolutionary events during sorafenib/regorafenib treatment. Twenty‐eight LT patients (57 years, 7% cirrhotics, 54% performance status 1) were included. Median time from LT to regorafenib initiation was 3.9 (1.1‐18.5) years; median time on sorafenib was 11.3 (0.7‐76.4) months and 14 (1‐591) days from sorafenib discontinuation to regorafenib. During regorafenib (6.3 months), all patients had at least one adverse event (AE), the most common grade 3/4 AEs were fatigue (n = 7) and dermatological reaction (n = 5). While no liver rejection was observed, plasma levels of immunosuppressive drugs increased in five. Twenty‐four patients developed progression (38% extrahepatic growth, 33% new extrahepatic lesions/vascular invasion). Median OS from regorafenib initiation was 12.9 (95% CI, 6.7‐19.1) and 38.4 months (95% CI, 18.5‐58.4) for the sorafenib initiation. This is the first study showing safety of regorafenib after LT, thus providing the rational of considering regorafenib in the clinical decision‐making in sorafenib‐tolerant patients with HCC recurrence after LT. This multicenter, international observational cohort study shows the safety of regorafenib in patients with recurrence of hepatocellular carcinoma after liver transplantation who tolerated sorafenib even though developing progression.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3
ISSN:	1600-6135 1600-6143
DOI:	10.1111/ajt.15551